Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04264208 · ClinicalTrials.gov registry record · Phase 2
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
A Phase 2 study, sponsored by Andrei Iagaru.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04264208: Clinical Trial Phase 2 study, sponsored by Andrei Iagaru.
NCT04264208 is a Phase 2 study that was terminated before completion, run by Andrei Iagaru. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04264208, a Phase 2 study, was terminated before completion, sponsored by Andrei Iagaru.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)
Primary Outcome
Assessment of whether 68-Ga-RM2 and 68-Ga-PSMA-11 PET/MRI can detect additional cancers over mpMRI. Detection of PC lesions will be assessed by 68Ga PSMA11 and 68Ga RM2 PET scans.
Interventions
- DEVICE PET/MRI
- DRUG 68-Ga PSMA11
- DRUG 68-Ga RM2.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-02-05 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 2 |
Why NCT04264208 stopped before completion
NCT04264208 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which PET/MRI is the first listed.
NCT04264208 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04264208 about?
NCT04264208 is a clinical study titled "HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer". This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)
What is the current status of trial NCT04264208?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2020-02-05. Estimated completion is 2022-12-14.
What interventions are being tested in trial NCT04264208?
The interventions under investigation include: PET/MRI (DEVICE), 68-Ga PSMA11 (DRUG), 68-Ga RM2. (DRUG).
Who is sponsoring clinical trial NCT04264208?
This trial is sponsored by Andrei Iagaru, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04264208's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI